Glycomark is a biotechnology company based in New York, New York, specializing in advanced diagnostic solutions related to diabetes management. Located in the 10022 postal code area, Glycomark focuses on the development and distribution of innovative biomarkers and testing methods designed to enhance precision medicine for diabetes. The company is known for its role in supplying the GlycoMark test, a blood assay that provides critical insights into recent hyperglycemia and glycemic variability, important factors in diabetes care.
The GlycoMark test utilizes 1,5-Anhydroglucitol as a biomarker, offering healthcare providers a detailed view of short-term glucose fluctuations that traditional tests may not capture. This test has received FDA clearance and CE marking, underscoring its regulatory compliance and acceptance in multiple international markets. Glycomark’s technology supports clinicians in assessing pancreatic beta-cell function and monitoring glycemic control, aiding in more tailored and effective treatment strategies for patients with diabetes.
Operating from its office on 3rd Avenue, Glycomark extends its reach beyond the United States, serving markets in Europe, Australia, the Asia-Pacific region, the Middle East, and Mexico. The company’s expertise in biotechnology enables it to contribute to the broader field of metabolic disease diagnostics, leveraging scientific research to provide actionable clinical information. Glycomark’s work aligns with ongoing advancements in personalized medicine, aiming to improve health outcomes through precise measurement tools.
As a specialized biotechnology company, Glycomark plays a critical role in the intersection of laboratory science and clinical practice. Its focus on diabetes biomarkers positions it within a dynamic industry segment dedicated to developing new technologies that respond to the evolving needs of patients and healthcare providers. The company’s commitment to innovation and accuracy supports the growing demand for diagnostic solutions that enable more informed decision-making in diabetes care.


































